{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:20:56Z","timestamp":1792790456172,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12916-018-1213-5","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T17:12:17Z","timestamp":1543857137000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines"],"prefix":"10.1186","volume":"16","author":[{"given":"Pieter T.","family":"de Boer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alies","family":"van Lier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester","family":"de Melker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert J. M.","family":"van Wijck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan C.","family":"Wilschut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert Jan","family":"van Hoek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J.","family":"Postma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,6]]},"reference":[{"issue":"18","key":"1213_CR1","first-page":"1766","volume":"369","author":"JI Cohen","year":"2013","unstructured":"Cohen JI. Herpes zoster. N Engl J Med. 2013;369(18):1766\u20137.","journal-title":"N Engl J Med"},{"issue":"44","key":"1213_CR2","doi-asserted-by":"publisher","first-page":"5127","DOI":"10.1016\/j.vaccine.2013.08.029","volume":"31","author":"A van Lier","year":"2013","unstructured":"van Lier A, Smits G, Mollema L, Waaijenborg S, Berbers G, van der Klis F, Boot H, Wallinga J, de Melker H. Varicella zoster virus infection occurs at a relatively young age in the Netherlands. Vaccine. 2013;31(44):5127\u201333.","journal-title":"Vaccine"},{"key":"1213_CR3","unstructured":"National Institute for Public Health and the Environment. In: Schurink-van \u2018t Klooster TM, de Melker H, editors. The National Immunisation Programme in the Netherlands. Bilthoven: surveillance and developments in 2016\u20132017; 2017."},{"issue":"3","key":"1213_CR4","first-page":"207","volume":"75","author":"C Schroder","year":"2017","unstructured":"Schroder C, Enders D, Schink T, Riedel O. Incidence of herpes zoster amongst adults varies by severity of immunosuppression. J Inf Secur. 2017;75(3):207\u201315.","journal-title":"J Inf Secur"},{"issue":"1","key":"1213_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12916-018-1094-7","volume":"16","author":"A Melegaro","year":"2018","unstructured":"Melegaro A, Marziano V, Del Fava E, Poletti P, Tirani M, Rizzo C, Merler S. The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness study. BMC Med. 2018;16(1):117.","journal-title":"BMC Med"},{"issue":"6","key":"1213_CR6","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/papr.12518","volume":"17","author":"AJM van Wijck","year":"2017","unstructured":"van Wijck AJM, Aerssens YR. Pain, itch, quality of life, and costs after herpes zoster. Pain Pract. 2017;17(6):738\u201346.","journal-title":"Pain Pract"},{"issue":"5","key":"1213_CR7","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/fampra\/19.5.471","volume":"19","author":"W Opstelten","year":"2002","unstructured":"Opstelten W, Mauritz JW, de Wit NJ, van Wijck AJ, Stalman WA, van Essen GA. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract. 2002;19(5):471\u20135.","journal-title":"Fam Pract"},{"issue":"7264","key":"1213_CR8","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1136\/bmj.321.7264.794","volume":"321","author":"S Helgason","year":"2000","unstructured":"Helgason S, Petursson G, Gudmundsson S, Sigurdsson JA. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ. 2000;321(7264):794\u20136.","journal-title":"BMJ"},{"issue":"11","key":"1213_CR9","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1586\/14737175.7.11.1581","volume":"7","author":"RW Johnson","year":"2007","unstructured":"Johnson RW, Wasner G, Saddier P, Baron R. Postherpetic neuralgia: epidemiology, pathophysiology and management. Expert Rev Neurother. 2007;7(11):1581\u201395.","journal-title":"Expert Rev Neurother"},{"key":"1213_CR10","unstructured":"European Medicines Agency. Zostavax: EPAR - Product Information 2009 \n                    https:\/\/www.ema.europa.eu\/documents\/product-information\/zostavax-epar-product-information_en.pdf\n                    \n                  . Accessed at 1 Oct 2018."},{"issue":"22","key":"1213_CR11","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa051016","volume":"352","author":"MN Oxman","year":"2005","unstructured":"Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271\u201384.","journal-title":"N Engl J Med"},{"issue":"6","key":"1213_CR12","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/cid\/ciu918","volume":"60","author":"VA Morrison","year":"2015","unstructured":"Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, Betts R, Gelb L, Guatelli JC, Harbecke R, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015;60(6):900\u20139.","journal-title":"Clin Infect Dis"},{"key":"1213_CR13","unstructured":"Health council of the Netherlands. Vaccination against shingles [In Dutch]; 2016. \n                    https:\/\/www.gezondheidsraad.nl\/documenten\/adviezen\/2016\/06\/29\/vaccinatie-tegen-gordelroos\n                    \n                  . Accessed 1 Sept 2018."},{"issue":"6","key":"1213_CR14","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/cid\/ciw854","volume":"64","author":"HS Izurieta","year":"2017","unstructured":"Izurieta HS, Wernecke M, Kelman J, Wong S, Forshee R, Pratt D, Lu Y, Sun Q, Jankosky C, Krause P, et al. Effectiveness and duration of protection provided by the live-attenuated herpes zoster vaccine in the Medicare population ages 65 years and older. Clin Infect Dis. 2017;64(6):785\u201393.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1213_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/aje\/kwx245","volume":"187","author":"R Baxter","year":"2018","unstructured":"Baxter R, Bartlett J, Fireman B, Marks M, Hansen J, Lewis E, Aukes L, Chen Y, Klein NP, Saddier P. Long-term effectiveness of the live zoster vaccine in preventing shingles: a cohort study. Am J Epidemiol. 2018;187(1):161\u20139.","journal-title":"Am J Epidemiol"},{"issue":"12","key":"1213_CR16","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1093\/infdis\/jiw047","volume":"213","author":"HF Tseng","year":"2016","unstructured":"Tseng HF, Harpaz R, Luo Y, Hales CM, Sy LS, Tartof SY, Bialek S, Hechter RC, Jacobsen SJ. Declining effectiveness of herpes zoster vaccine in adults aged \u226560 years. J Infect Dis. 2016;213(12):1872\u20135.","journal-title":"J Infect Dis"},{"issue":"5","key":"1213_CR17","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1080\/21645515.2015.1016681","volume":"11","author":"M Marin","year":"2015","unstructured":"Marin M, Yawn BP, Hales CM, Wollan PC, Bialek SR, Zhang J, Kurland MJ, Harpaz R. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status. Hum Vaccin Immunother. 2015;11(5):1157\u201364.","journal-title":"Hum Vaccin Immunother"},{"key":"1213_CR18","unstructured":"European Medicines Agency. Shingrix: EPAR - Product Information 2018 \n                    https:\/\/www.ema.europa.eu\/documents\/product-information\/shingrix-epar-product-information_en.pdf\n                    \n                  . Accessed at 1 Oct 2018."},{"issue":"22","key":"1213_CR19","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barbera J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087\u201396.","journal-title":"N Engl J Med"},{"issue":"11","key":"1213_CR20","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barbera J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019\u201332.","journal-title":"N Engl J Med"},{"key":"1213_CR21","doi-asserted-by":"crossref","unstructured":"Le P, Rothberg MB. Cost-effectiveness of the adjuvanted herpes zoster subunit vaccine in older adults. JAMA Intern Med. 2018;178(2):248\u2013258.","DOI":"10.1001\/jamainternmed.2017.7431"},{"key":"1213_CR22","unstructured":"Van Oorschot D, Anastassopoulou A, Poulsen Nautrup B, Varghese L, von Krempelhuber A, Neine M, Lorenc S, Curran D. Cost-effectiveness of the recombinant zoster vaccine in the German population aged \u226560 years old. Hum Vaccin Immunother. 2018;21:1\u201311."},{"issue":"31","key":"1213_CR23","doi-asserted-by":"publisher","first-page":"4610","DOI":"10.1016\/j.vaccine.2018.06.049","volume":"36","author":"JHS You","year":"2018","unstructured":"You JHS, Ming WK, Lee CF, Tsang OT, Chan PK. Potential cost-effectiveness of adjuvanted herpes zoster subunit vaccine for older adults in Hong Kong. Vaccine. 2018;36(31):4610\u201320.","journal-title":"Vaccine"},{"issue":"33","key":"1213_CR24","doi-asserted-by":"publisher","first-page":"5037","DOI":"10.1016\/j.vaccine.2018.07.005","volume":"36","author":"D Curran","year":"2018","unstructured":"Curran D, Patterson B, Varghese L, Van Oorschot D, Buck P, Carrico J, Hicks K, Lee B, Yawn B. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States. Vaccine. 2018;36(33):5037\u201345.","journal-title":"Vaccine"},{"key":"1213_CR25","unstructured":"National Health Care Institute. Cost-effectiveness in practice [In Dutch]; 2015 \n                    https:\/\/www.zorginstituutnederland.nl\/binaries\/zinl\/documenten\/rapport\/2015\/06\/26\/kosteneffectiviteit-in-de-praktijk\/Kosteneffectiviteit+in+de+praktijk.pdf\n                    \n                  . Accessed 1 Sept 2018."},{"issue":"1","key":"1213_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/infdis\/jiv480","volume":"213","author":"MJ Levin","year":"2016","unstructured":"Levin MJ, Schmader KE, Pang L, Williams-Diaz A, Zerbe G, Canniff J, Johnson MJ, Caldas Y, Cho A, Lang N, et al. Cellular and humoral responses to a second dose of herpes zoster vaccine administered 10 years after the first dose among older adults. J Infect Dis. 2016;213(1):14\u201322.","journal-title":"J Infect Dis"},{"key":"1213_CR27","unstructured":"National Health Care Institute. Guideline for economic evaluations in healthcare 2016 \n                    https:\/\/english.zorginstituutnederland.nl\/publications\/reports\/2016\/06\/16\/guideline-for-economic-evaluations-in-healthcare\n                    \n                  . Accessed at 1 Dec 2017."},{"key":"1213_CR28","unstructured":"Statistics Netherlands. Life-expectancy; gender, age (per year and period of five years); 2017. \n                    http:\/\/statline.cbs.nl\/Statweb\/publication\/?DM=SLNL&PA=37360ned&D1=0&D2=0&D3=a&D4=94-95%2cl&HDR=G1%2cT&STB=G2%2cG3&VW=T\n                    \n                  . Accessed 1 Dec 2017."},{"key":"1213_CR29","unstructured":"Statistics Netherlands. Population; gender, age, marital status and region, 1 January 2017. \n                    http:\/\/statline.cbs.nl\/Statweb\/publication\/?DM=SLNL&PA=03759ned&D1=0-2&D2=0-117&D3=0&D4=l&HDR=T&STB=G2,G3,G1&VW=T\n                    \n                  . Accessed 1 Dec 2017."},{"key":"1213_CR30","unstructured":"Netherlands Institute for Health Services Research (NIVEL). NIVEL healtcare registrations first line 2017 \n                    https:\/\/www.nivel.nl\/nl\/nzr\/zorgregistraties-eerstelijn\n                    \n                  . Accessed at 1 Dec 2017."},{"issue":"9","key":"1213_CR31","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.vaccine.2008.12.024","volume":"27","author":"AJ van Hoek","year":"2009","unstructured":"van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine. 2009;27(9):1454\u201367.","journal-title":"Vaccine"},{"key":"1213_CR32","unstructured":"Dutch Hospital Data (DHD). Landelijke basisregistratie ziekenhuiszorg (LBZ) [Dutch national registration hospital care] 2017 \n                    https:\/\/www.dhd.nl\/producten-diensten\/LBZ\/Paginas\/Dataverzameling-LBZ.aspx\n                    \n                  . Accessed at 1 Dec 2017."},{"issue":"7","key":"1213_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0180797","volume":"12","author":"E Beninca","year":"2017","unstructured":"Beninca E, van Boven M, Hagenaars T, van der Hoek W. Space-time analysis of pneumonia hospitalisations in the Netherlands. PLoS One. 2017;12(7):e0180797.","journal-title":"PLoS One"},{"key":"1213_CR34","unstructured":"Statistics Netherlands. Deceased; cause of death (extended list), age, gender 2017. \n                    http:\/\/statline.cbs.nl\/Statweb\/publication\/?DM=SLNL&PA=7233&D1=90&D2=0&D3=12-21&D4=13-20&HDR=G2%2cG1%2cG3&STB=T&VW=T\n                    \n                  . Accessed 1 Dec 2017."},{"issue":"7","key":"1213_CR35","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1093\/cid\/cis575","volume":"55","author":"A Mahamud","year":"2012","unstructured":"Mahamud A, Marin M, Nickell SP, Shoemaker T, Zhang JX, Bialek SR. Herpes zoster-related deaths in the United States: validity of death certificates and mortality rates, 1979\u20132007. Clin Infect Dis. 2012;55(7):960\u20136.","journal-title":"Clin Infect Dis"},{"key":"1213_CR36","unstructured":"Szende A, Janssen B, Cabases J. Self-reported population health: an international perspective based on EQ-5D: Springer Open; 2014. \n                    https:\/\/link.springer.com\/content\/pdf\/10.1007%2F978-94-007-7596-1.pdf\n                    \n                  . Accessed 1 Sept 2018."},{"key":"1213_CR37","unstructured":"Statistics Netherlands. Consumer prices; price index 2015=100 2017 \n                    http:\/\/statline.cbs.nl\/Statweb\/publication\/?DM=SLEN&PA=83131ENG&D1=0&D2=0&D3=64,77,90,103,116,129,142,155,168,181,194,207,220,233,246,259,272,285&LA=EN&HDR=T&STB=G1,G2&VW=T\n                    \n                  . Accessed 1 Dec 2017."},{"key":"1213_CR38","unstructured":"Hakkaart-van Roijen L, Tan SS, Bouwmans CAM. Guidance for costing research; methods and standardized prices for economic evaluations in health care [In Dutch]; 2010. \n                    https:\/\/docplayer.nl\/6361834-Handleiding-voor-kostenonderzoek-methoden-en-standaard-kostprijzen-voor-economische-evaluaties-in-de-gezondheidszorg.html\n                    \n                  . Accessed 1 Sept 2018."},{"issue":"11","key":"1213_CR39","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s40273-016-0431-y","volume":"34","author":"M Versteegh","year":"2016","unstructured":"Versteegh M, Knies S, Brouwer W. From good to better: new Dutch guidelines for economic evaluations in healthcare. Pharmacoeconomics. 2016;34(11):1071\u20134.","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"1213_CR40","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2165\/11586130-000000000-00000","volume":"29","author":"PH van Baal","year":"2011","unstructured":"van Baal PH, Wong A, Slobbe LC, Polder JJ, Brouwer WB, de Wit GA. Standardizing the inclusion of indirect medical costs in economic evaluations. Pharmacoeconomics. 2011;29(3):175\u201387.","journal-title":"Pharmacoeconomics"},{"key":"1213_CR41","unstructured":"Stichting Nationaal Programma Grieppreventie (SNPG). Fee (In Dutch); 2017. \n                    https:\/\/www.snpg.nl\/article\/declareren-griepvaccinaties\/vergoeding\/\n                    \n                  . Accessed at 1 Dec 2017."},{"issue":"21","key":"1213_CR42","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1016\/j.vaccine.2017.04.014","volume":"35","author":"R Eilers","year":"2017","unstructured":"Eilers R, de Melker HE, Veldwijk J, Krabbe PFM. Vaccine preferences and acceptance of older adults. Vaccine. 2017;35(21):2823\u201330.","journal-title":"Vaccine"},{"issue":"5","key":"1213_CR43","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1183\/13993003.00325-2015","volume":"46","author":"MJ Mangen","year":"2015","unstructured":"Mangen MJ, Rozenbaum MH, Huijts SM, van Werkhoven CH, Postma DF, Atwood M, van Deursen AM, van der Ende A, Grobbee DE, Sanders EA, et al. Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Respir J. 2015;46(5):1407\u201316.","journal-title":"Eur Respir J"},{"issue":"7","key":"1213_CR44","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/cid\/cir970","volume":"54","author":"KE Schmader","year":"2012","unstructured":"Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359 years. Clin Infect Dis. 2012;54(7):922\u20138.","journal-title":"Clin Infect Dis"},{"key":"1213_CR45","unstructured":"Rohan P. FDA Clinical Briefing Document for Merck & Co., Inc. Zoster vaccine live (Oka\/Merck) Zostavax\u2122; 2005. \n                    http:\/\/citeseerx.ist.psu.edu\/viewdoc\/download?doi=10.1.1.177.2250&rep=rep1&type=pdf\n                    \n                  . Accessed 1 Dec 2017."},{"issue":"10","key":"1213_CR46","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/cid\/cis638","volume":"55","author":"KE Schmader","year":"2012","unstructured":"Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, Morrison VA, Gelb L, Guatelli JC, Harbecke R, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012;55(10):1320\u20138.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"1213_CR47","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1080\/21645515.2017.1345399","volume":"13","author":"D Curran","year":"2017","unstructured":"Curran D, Van Oorschot D, Varghese L, Oostvogels L, Mrkvan T, Colindres R, von Krempelhuber A, Anastassopoulou A. Assessment of the potential public health impact of herpes zoster vaccination in Germany. Hum Vaccin Immunother. 2017;13(10):2213\u201321.","journal-title":"Hum Vaccin Immunother"},{"key":"1213_CR48","doi-asserted-by":"publisher","first-page":"c2509","DOI":"10.1136\/bmj.c2509","volume":"340","author":"MH Rozenbaum","year":"2010","unstructured":"Rozenbaum MH, Sanders EA, van Hoek AJ, Jansen AG, van der Ende A, van den Dobbelsteen G, Rodenburg GD, Hak E, Postma MJ. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ. 2010;340:c2509.","journal-title":"BMJ"},{"issue":"3","key":"1213_CR49","first-page":"241","volume":"73","author":"PH Hobbelen","year":"2016","unstructured":"Hobbelen PH, Stowe J, Amirthalingam G, Miller L, van Hoek AJ. The burden of hospitalisation for varicella and herpes zoster in England from 2004 to 2013. J Inf Secur. 2016;73(3):241\u201353.","journal-title":"J Inf Secur"},{"key":"1213_CR50","doi-asserted-by":"crossref","unstructured":"Walker JL, Andrews NJ, Amirthalingam G, Forbes H, Langan SM, Thomas SL. Effectiveness of herpes zoster vaccination in an older United Kingdom population. Vaccine. 2018.","DOI":"10.1016\/j.vaccine.2018.02.021"},{"key":"1213_CR51","doi-asserted-by":"publisher","first-page":"f1049","DOI":"10.1136\/bmj.f1049","volume":"346","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ. 2013;346:f1049.","journal-title":"BMJ"},{"issue":"7","key":"1213_CR52","doi-asserted-by":"publisher","first-page":"A556","DOI":"10.1016\/j.jval.2014.08.1831","volume":"17","author":"P Vemer","year":"2014","unstructured":"Vemer P, Corro Ramos I, Van Voorn G, Al MJ, Feenstra TL. AdVISHE: a new tool to report validation of health-economic decision models. Value Health. 2014;17(7):A556\u20137.","journal-title":"Value Health"},{"key":"1213_CR53","unstructured":"Centers for Disease Control and Prevention. Adult Vaccine Price List 2018 \n                    https:\/\/www.cdc.gov\/vaccines\/programs\/vfc\/awardees\/vaccine-management\/price-list\/index.html\n                    \n                  . Accessed at 1 Oct 2018."},{"key":"1213_CR54","unstructured":"National Health Care Institute. Medicijnkosten.nl 2017 \n                    www.medicijnkosten.nl\n                    \n                  . Accessed at 1 Dec 2017."},{"issue":"4","key":"1213_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001420","volume":"10","author":"SM Langan","year":"2013","unstructured":"Langan SM, Smeeth L, Margolis DJ, Thomas SL. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med. 2013;10(4):e1001420.","journal-title":"PLoS Med"},{"issue":"1","key":"1213_CR56","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.vaccine.2017.08.029","volume":"36","author":"MJ Levin","year":"2018","unstructured":"Levin MJ, Buchwald UK, Gardner J, Martin J, Stek JE, Brown E, Popmihajlov Z. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine. 2018;36(1):179\u201385.","journal-title":"Vaccine"},{"issue":"11","key":"1213_CR57","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/infdis\/jix481","volume":"216","author":"TF Schwarz","year":"2017","unstructured":"Schwarz TF, Aggarwal N, Moeckesch B, Schenkenberger I, Claeys C, Douha M, Godeaux O, Grupping K, Heineman TC, Fauqued ML, et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine coadministered with seasonal influenza vaccine in adults aged 50 years or older. J Infect Dis. 2017;216(11):1352\u201361.","journal-title":"J Infect Dis"},{"issue":"1","key":"1213_CR58","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.vaccine.2017.11.019","volume":"36","author":"H Lal","year":"2018","unstructured":"Lal H, Poder A, Campora L, Geeraerts B, Oostvogels L, Vanden Abeele C, Heineman TC. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine. 2018;36(1):148\u201354.","journal-title":"Vaccine"},{"issue":"3","key":"1213_CR59","doi-asserted-by":"publisher","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","volume":"67","author":"KL Dooling","year":"2018","unstructured":"Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, Harpaz R. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR Morb Mortal Wkly Rep. 2018;67(3):103\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"Suppl 2","key":"1213_CR60","doi-asserted-by":"publisher","first-page":"S237","DOI":"10.1086\/522129","volume":"197","author":"JI Cohen","year":"2008","unstructured":"Cohen JI. Strategies for herpes zoster vaccination of immunocompromised patients. J Infect Dis. 2008;197(Suppl 2):S237\u201341.","journal-title":"J Infect Dis"},{"key":"1213_CR61","unstructured":"Health Council of the Netherlands. The individual, collective and public relevance of vaccination; 2013. \n                    https:\/\/www.gezondheidsraad.nl\/over-ons\/documenten\/adviezen\/2013\/10\/03\/het-individuele-collectieve-en-publieke-belang-van-vaccinatie\n                    \n                  . Accessed 1 Sept 2018."},{"key":"1213_CR62","unstructured":"National Health Service. Shingles vaccination 2015 \n                    https:\/\/www.nhs.uk\/Conditions\/vaccinations\/Pages\/shingles-vaccination.aspx\n                    \n                  . Accessed at 1 Dec 2017."},{"key":"1213_CR63","unstructured":"Immunisation and High Consequence Infectious Diseases Team GaPHG. Consultation on the Cost-Effectiveness Methodology for Vaccination Programmes and Procurement (CEMIPP) Report 2018 \n                    https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/683841\/Consultation_document_re_CEMIPP.pdf\n                    \n                  . Accessed at 1 June 2018."},{"key":"1213_CR64","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/1471-2334-13-170","volume":"13","author":"S Pinchinat","year":"2013","unstructured":"Pinchinat S, Cebrian-Cuenca AM, Bricout H, Johnson RW. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis. 2013;13:170.","journal-title":"BMC Infect Dis"},{"issue":"9","key":"1213_CR65","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1001\/jamainternmed.2018.3200","volume":"178","author":"P Le","year":"2018","unstructured":"Le P, Rothberg MB. Cost-effectiveness of the recommendations of the Advisory Committee on Immunization Practices for the recombinant adjuvanted zoster subunit vaccine. JAMA Intern Med. 2018;178(9):1277\u20138.","journal-title":"JAMA Intern Med"},{"key":"1213_CR66","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/1472-6963-10-237","volume":"10","author":"A van Lier","year":"2010","unstructured":"van Lier A, van Hoek AJ, Opstelten W, Boot HJ, de Melker HE. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Serv Res. 2010;10:237.","journal-title":"BMC Health Serv Res"},{"issue":"9","key":"1213_CR67","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.vaccine.2012.12.067","volume":"31","author":"PT de Boer","year":"2013","unstructured":"de Boer PT, Pouwels KB, Cox JM, Hak E, Wilschut JC, Postma MJ. Cost-effectiveness of vaccination of the elderly against herpes zoster in the Netherlands. Vaccine. 2013;31(9):1276\u201383.","journal-title":"Vaccine"},{"key":"1213_CR68","unstructured":"ClinicalTrials.gov\n                    \n                  . A long-term follow-up study (ZOE-LTFU) of two studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to assess the efficacy, safety, and immunogenicity persistence of GSK biologicals\u2019 herpes zoster subunit (HZ\/su) vaccine and assessment of 1 or 2 additional doses in two subgroups of older adults 2016 \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02723773?cond=hz%2Fsu&rank=6\n                    \n                  . Accessed at 1 Dec 2017."},{"key":"1213_CR69","unstructured":"GSK. New data supports the safety and efficacy of GSK\u2019s Shingrix in preventing shingles in autologous haematopoietic stem cell transplant patients 2017 \n                    https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/new-data-supports-the-safety-and-efficacy-of-gsk-s-shingrix-in-preventing-shingles-in-autologous-haematopoietic-stem-cell-transplant-patients\/\n                    \n                  . Accessed at 15 Jan 2017."},{"issue":"5","key":"1213_CR70","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/j.1399-3062.2011.00655.x","volume":"13","author":"JE Rogers","year":"2011","unstructured":"Rogers JE, Cumpston A, Newton M, Craig M. Onset and complications of varicella zoster reactivation in the autologous hematopoietic cell transplant population. Transpl Infect Dis. 2011;13(5):480\u20134.","journal-title":"Transpl Infect Dis"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-018-1213-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12916-018-1213-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-018-1213-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T00:10:24Z","timestamp":1575591024000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-018-1213-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1213"],"URL":"https:\/\/doi.org\/10.1186\/s12916-018-1213-5","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"5 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"None required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No external funding has been received for this study. PTdB, AvL, HdM and AJvH report no conflict of interest. AJMvW has received a grant from Sanofi Pasteur MSD, which was unrelated to this project. JCW and MJP have received grants and honoraria from various pharmaceutical companies, including those developing, producing and marketing zoster vaccines, but all unrelated to this project.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"228"}}